Nura Bio secured a $73.8 million Series B round to fund two programs through early clinical development targeting SARM1 for neurodegeneration. The company said it will use the funding to support ongoing clinical work and expand development plans into early human studies. SARM1 inhibitors are being developed to modulate axon degeneration pathways, a mechanism that has attracted attention in neurodegenerative disease research. Investors will watch early readouts for target engagement and signals related to clinical outcomes, including measures of neurological function and safety. The financing highlights continuing capital formation in neurodegeneration drug development, particularly in pathway-directed approaches that aim at mechanisms upstream of clinical decline. Next milestones for Nura will include progress toward dose selection and initial pharmacodynamic and clinical endpoints that can guide Phase 2 planning.